louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04241081: Interrupting Prolonged Sitting With Periodic Interval Exercise: Effect on Postprandial Lipemia
Official title: Interrupting Prolonged Sitting With Periodic Interval Exercise: Effect on Postprandial Lipemia
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Sedentary Behavior
Hypertriglyceridemia
Lead sponsor: University of Texas at Austin
Sponsor class: OTHER
First posted: 2020-01-27
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Investigating the effects of interrupting various lengths of prolonged sitting with bike sprints on post prandial lipemia the next day. We will conduct three trials, one control, one with two-hour sitting intervals (total of 4 bouts of bike sprints) and one with 6-hour sitting intervals I total of two bouts of bike sprints). A milkshake high fat tolerance test will be conducted the next day and whole body fat oxidation as well as triglyceride area under the curve will be measured every hour for the duration of the 6-hour test.


Eligibility criteria: Inclusion Criteria:

* Inactive or recreational healthy adults aged 18-65 years old.

Exclusion Criteria:

* Lactose intolerance, cardiovascular or metabolic diagnoses, medications for cardiovascular or metabolic diagnoses, orthopedic issues barring cycling.

Primary outcomes:
measure: Triglyceride area under the curve
timeFrame: 6 hour long high fat tolerance test
Secondary outcomes:
measure: Whole body fat oxidation
timeFrame: 10 min, baseline, 2 hours post ingestion of shake, 4 hours, 6 hours.
Other outcomes:
Locations:
city: Austin
country: United States
facility: University of Texas, Austin
state: Texas
Study officials:
References:
Clinical trial NCT01972581: Neurocognitive Visual Reaction Training
Official title: Neurocognitive Visual Reaction Training
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Reaction Time
Keywords: neurocognitive visual reaction training
baseball
Lead sponsor: High Point University
Sponsor class: OTHER
First posted: 2013-10-30
Enrollment: 21
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Incorporating neurocognitive visual reaction training has been shown to increase bating performance in collegiate baseball players. However, poor methodology, such as lack of a control group and use of an unreliable outcome measure, limit the strength of the previous study. Therefore the purpose of this study is to determine the effects of neurocognitive visual reaction training on reaction time and coordination in an athletic population.

The purpose of this study is to determine the effects of neurocognitive visual reaction training on reaction time and coordination.


Eligibility criteria: Inclusion Criteria:

* subjects that participate in a structured sport team
* between the ages of 18-65
* with or without a history of mild traumatic brain injury.

Exclusion Criteria:

* subjects currently under medical supervision and not fully cleared to participate in structured sport team.

Primary outcomes:
measure: Number of colored balls correctly identified
timeFrame: 5 weeks
Secondary outcomes:
measure: Number of ball catches on alternate ball toss
timeFrame: 5 weeks
measure: Reaction time on dynavision reaction board
timeFrame: 5 Weeks
Other outcomes:
Locations:
city: High Point
country: United States
facility: Human Biomechanics and Physiology Laboratory
state: North Carolina
Study officials:
affiliation: High Point University
name: Kevin Ford, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01824381: Use of the Amniotic Membrane in Large Wound Epithelialization
Official title: Use of the Amniotic Membrane in Large Wound Epithelialization. Phase I Clinical Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Wounds
Keywords: extensive wounds
amniotic membrane
healing
patients
phase granulation
Lead sponsor: Red de Terapia Celular
Sponsor class: INDUSTRY
Collaborators: name: Public Health Service, Murcia
name: Universidad de Murcia
name: Hospital Universitario Virgen de la Arrixaca
name: MurciaSalud
First posted: 2013-04-04
Enrollment: 6
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to analyze the security application of the amniotic membrane in extensive wounds in the granulation phase.


Eligibility criteria: Inclusion Criteria:

* Acute wounds in granulation phase with a minimum area of 100 cm2.
* Patients 18 or more years.
* Patients offering sufficient guarantees of adherence to protocol.
* Sign the written informed consent.
* Meet all inclusion criteria.

Exclusion Criteria:

* Patients with symptomatic chronic arterial insufficiency.
* Patients who are pregnant
* Patients in active lactation
* Patients physically fertile, defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle or sexual orientation precludes intercourse with a man and women whose partners have been sterilized by vasectomy or other methods, UNLESS they are using reliable contraception. This method of contraception can be:

  * Complete abstinence from sexual intercourse
  * Surgical sterilization (tubal ligation)
  * Surgical sterilization of the partner (vasectomy)
  * Implanted or injectable hormonal contraceptives, oral \*
  * Because hormonal contraceptives have a risk of thrombosis, should consider other methods of birth control.

These reliable contraception must be maintained during their participation in the study.

* Patients with heart, kidney, liver, systemic immune may influence the survival of the patient during the test.
* Participation in other clinical trials.
* Inability to understand informed consent.

Primary outcomes:
measure: Safety
timeFrame: Last revision at 3 years after surgery.
Secondary outcomes:
measure: Measurement of the wound area
timeFrame: 3 years
measure: Evolution of local pain measured with a visual analog scale
timeFrame: 1 year
measure: Changes in the signaling pathways of TGFb.
timeFrame: 1 year
Other outcomes:
Locations:
city: El Palmar
country: Spain
facility: Clinical Universitary Hospital Virgen de la Arrixaca
state: Murcia
Study officials:
affiliation: Clinical Universitary Hospital Virgen de la Arrixaca
name: Gregorio Castellanos-Escrig, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04330781: Radiotherapy of Head and Neck Cancer Using an Intraoral Stent
Official title: Patient-reported Outcome After Radiotherapy of Oral Cavity and Sinonasal Cancer Using an Intraoral Stent
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Oral Cavity Cancer
Sinonasal Cancer
Keywords: Radiotherapy
Intraoral stent
Head and neck cancer
Patient-reported outcome
Lead sponsor: Oslo University Hospital
Sponsor class: OTHER
Collaborators: name: Oslo Metropolitan University
First posted: 2020-04-01
Enrollment: 210
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Radiotherapy of oral cavity cancer and sinonasal cancer is associated with acute and late morbidity. Use of an intraoral stent will provide a larger distance between the tongue and palate and can reduce side-effects. The aim of the present study is to confirm that an intraoral stent is not a significant bother to the patients.

Detailed description: The investigators have previously performed a pilot study on the feasibility of the intraoral stent in patients receiving radiotherapy for tongue cancer. It was found that most of the patients tolerated the stent. The mean radiation dose to the hard palate was reduced by 61% (absolute percentage) as compared with a control group not using the stent. Based on these results, the investigators wish to perform a study on a larger cohort to confirm that the intraoral stent will not lead to increased symptoms towards the end of the radiotherapy period.

Eligibility criteria: Inclusion Criteria:

* Radiation dose 30 Gy or higher
* Cancer in the inferior part of the oral cavity (e.g. tongue or floor of mouth cancer) or superior part of the oral cavity (e.g. hard palate) or sinonasal cancer
* Eastern Cooperative Oncology Group (ECOG) performance status 0-3
* Ability to understand and answer questionnaire

Exclusion Criteria: None

Primary outcomes:
measure: Patient-reported outcome
timeFrame: At the end of radiotherapy (5-6 weeks)
Secondary outcomes:
Other outcomes:
Locations:
city: Oslo
country: Norway
facility: Oslo University Hospital
Study officials:
affiliation: Senior Consultant
name: Einar Dale, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Bø B, Furre T, Dale E. Radiotherapy of tongue cancer using an intraoral stent: a pilot study. Journal of Radiotherapy in Practice. 2021;21(3):370-6.
Clinical trial NCT01755481: Feeding Infant Formula With Added Probiotics and Whey Protein Concentrate
Official title: Feeding Infant Formula With Added Probiotics and Whey Protein Concentrate
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Focus on Healthy Infants
Lead sponsor: Arla Foods
Sponsor class: INDUSTRY
First posted: 2012-12-24
Enrollment: 800
Sex: ALL
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: To evaluate the effects of feeding an infant formula containing L. paracasei ssp. paracasei strain F19 or Whey Protein Concentrate.


Eligibility criteria: Inclusion criteria (formula-fed group):

healthy infants of mothers who could not or voluntarily resigned completely from breast-feeding at infant age 14 plus/minus 3 days

Inclusion criteria (breast-fed group):

healthy infants exclusively breast-fed from birth and mothers intending to breastfeed \>80% until at least 5th month of age (meaning through the 4th month of age).

Inclusion criteria (all infants):

delivered between 37 and 42 weeks of gestation birth weight \>2500 g and \<4000 g parent or the subject's legal representative speak and understand Chinese

Exclusion criteria (formula-fed group):

fully or partially breast-fed infants infants breast-fed \>20%

Exclusion criteria (breast-fed group):

infants fed \>20% infant formula

Exclusion criteria (all infants):

malformations, handicaps or congenital diseases that could affect normal feeding or growth treatment with antibiotics

Primary outcomes:
measure: Infections episodes (gastrointestinal and upper and lower respiratory infections)
timeFrame: 4 yrs
Secondary outcomes:
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Department of Child Health Care, Children's Hospital, Fudan University
Study officials:
affiliation: Children's Hospital, Fudan University, Shanghai, China
name: Yongmei Peng, M.D., Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06592781: Assessing the Knowledge and the Willingness to Accept Renal Transplantation As a Treatment Option Among CKD Patients
Official title: Assessing the Knowledge and the Willingness to Accept Renal Transplantation As a Treatment Option Among CKD Patients ,a Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Assessing the Knowledge and the Willingness to Accept Renal Transplantation As a Treatment Option Among CKD Patients, a Cross-sectional Study
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-09-19
Enrollment: 850
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 1. Age \&gt;18 years
2. Patients diagnosed to have CKD stage III- stage V (including patients undergoing regular haemodialysis) regardless the duration of the disease

Brief summary: Assessing the knowledge and the willingness to accept renal transplantation as a treatment option among CKD patients, a cross-sectional study

Detailed description: Kidney transplantation in CKD patient

Eligibility criteria: Inclusion Criteria:

* Age \&amp;gt;18 years
* Patients diagnosed to have CKD stage III- stage V (including patients undergoing regular haemodialysis) regardless the duration of the disease

Exclusion Criteria:

* CKD patients of stage I or II of the disease
* Patients with AKI
* Patients refusing to answer the questionnaire
* Patients who are unable to understand the questionnaire
* Patients underwent kidney transplantation

Primary outcomes:
measure: Assessment of the knowledge and the willingness of CKD patients to accept kidney transplantation
timeFrame: 18 months
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Boima V, Amissah-Arthur MB, Yorke E, Dey D, Fiagbe D, Yawson AE, Nonvignon J, Mate-Kole CC. Determinants of willingness to accept kidney transplantation among chronic kidney disease patients in Ghana. BMC Nephrol. 2021 Apr 13;22(1):129. doi: 10.1186/s12882-021-02335-9.
Clinical trial NCT06252181: Pain and Hemodynamics in Peripheral Arterial Disease: Response to Pulsed Electromagnetic Treatment
Official title: Pain and Hemodynamics in Peripheral Arterial Disease: Response to Pulsed Electromagnetic Treatment in Elderly
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Peripheral Arterial Disease
Lead sponsor: Ahram Canadian University
Sponsor class: OTHER
First posted: 2024-02-09
Enrollment: 40
Sex: MALE
Minimum age (years): 65
Maximum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: patients with peripheral arterial disease are recommended to perform all exercise forms including elliptical type. electromagnetic treatment addition to exercise may increase benefits of this exercise

Detailed description: patients (40 elderly) with peripheral arterial disease who take their medications will be divided to older patients group that receive one hour elliptical exercise (n=20 patients, exercise will be applied 3 times per the week for eight week) and a group (n=20) that receive 3 sessions per weeks of 8-week electromagnetic one-hour therapy and one hour elliptical exercise (exercise will be applied 3 times per the week for eight week)

Eligibility criteria: Inclusion Criteria:

* older patients
* peripheral arterial disease patients

Exclusion Criteria:

* cardiac elders
* respiratory elders
* renal elders

Primary outcomes:
measure: ankle brachial index
timeFrame: It will be measured after 8 weeks
Secondary outcomes:
measure: posterior tibial artery diameter
timeFrame: It will be measured after 8 weeks
measure: claudication pain time
timeFrame: It will be measured after 8 weeks
measure: claudication pain distance
timeFrame: It will be measured after 8 weeks
measure: Modified walking impairment questionnaire
timeFrame: It will be measured after 8 weeks
measure: six minute walking test (pain free distance)
timeFrame: It will be measured after 8 weeks
measure: six minute walking test (total walked distance)
timeFrame: it will be measured after 8 weeks
measure: intermittent claudication questionnaire
timeFrame: it will be measured after 8 weeks
measure: short form 36 health questionnaire
timeFrame: it will be measured after 8 weeks
measure: Short physical performance battery
timeFrame: it will be measured after 8 weeks
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Ahram canadian university
Study officials:
affiliation: Ahram Canadian University
name: hagar El-Hadidy, lecturer
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02473081: Minimal Psychological Intervention in Diabetes Patients
Official title: The Long-term Effect of a Minimal Psychological Intervention on Type 2 Diabetes Patients' Depressive Symptom, Diabetes-related Distress and Glycemic Control
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Diabetes Mellitus, Type 2
Depression
Keywords: Type 2 diabetes
Minimal psychological intervention
Glycemic control
Depressive symptoms
Problem Area in Diabetes
Middle-aged and older adults
HbA1c protein, human
Lead sponsor: National Cheng-Kung University Hospital
Sponsor class: OTHER
Collaborators: name: National Science and Technology Council, Taiwan
First posted: 2015-06-16
Enrollment: 182
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to determine whether the telephone-delivered Minimal Psychological Intervention (MPI) could improve diabetes' depressive symptom and diabetes-related immediately , as well as HbA1c level in the long-term.


Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of Diabetes disease

Exclusion Criteria:

* Were using anti-depression medication
* With ongoing psychological/psychiatric treatment
* Had been diagnosed with psychosis (ex. schizophrenia or bipolar disorder)
* Had severe cognitive problem or hearing impairment
* Lost their partner within three months

Primary outcomes:
measure: Depressive symptom assessed by CES-D 10
timeFrame: At three points in time: at baseline (wave 1), post-intervention or 6 weeks after randomization (wave 2), and 1 month after the intervention period or 10 weeks after randomization (wave 3)
measure: Diabetes-related distress assessed by PAID scale
timeFrame: At three points in time: at baseline (wave 1), post-intervention or 6 weeks after randomization (wave 2), and 1 month after the intervention period or 10 weeks after randomization (wave 3)
measure: Hemoglobin A1c
timeFrame: Participants were measured during entire follow-up period, an average period of 3 months.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT06365281: Caries Prevalence, Experience and Risk Related Factors Among Early Middle-aged Patients Attending Cairo University
Official title: Caries Prevalence, Experience and Risk Related Factors Among Early Middle-aged Patients Attending Faculty of Dentistry, Cairo University
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Dental Caries
Caries,Dental
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-04-15
Enrollment: 350
Sex: ALL
Minimum age (years): 35
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: 1. Patients whose age between 35 to 44 years old.
2. Patient consulting in the outpatient clinic
3. Provide informed consent
4. Co-operative patients approving to participate in the trial.
5. Males \& Females
6. Egyptian

Brief summary: Dental caries, a widespread oral health issue, results from a complex interplay of factors including behavior, hygiene, diet, and socio-demographic aspects. While preventive measures are available, it remains prevalent globally, affecting numerous teeth per individual. Improved oral hygiene practices and increased awareness have led to a reduction in caries prevalence. However, rising sugar consumption exceeds dietary guidelines, contributing to the problem. Despite limited epidemiological studies in Egypt, addressing individual-level factors is crucial. Surveillance of oral health in the early middle age group is standard, allowing decision-makers to assess the impact of caries and oral health care provision. Stratifying data by age, geography, and gender aids in understanding prevalence and planning effective prevention strategies. Overall, promoting awareness of dietary habits and preventive practices is vital for improving oral health outcome So, The purpose of this study is to assess the prevalence of dental caries among early middle age patients attending dental hospital in Faculty of Dentistry, Cairo university and to analyze the related risk factors utilizing WHO Oral Health Questionnaire for Adults.


Eligibility criteria: Inclusion Criteria:

1. Patients whose age between 35 to 44 years old.
2. Patient consulting in the outpatient clinic
3. Provide informed consent
4. Co-operative patients approving to participate in the trial.
5. Males \& Females
6. Egyptian

Exclusion Criteria:

1. Patients under or over this age group
2. Lack of compliance
3. Disabilities

Primary outcomes:
measure: Prevalence of dental caries
timeFrame: 1 year
Secondary outcomes:
measure: Caries experience
timeFrame: 1 year
measure: Caries risk related factors
timeFrame: 1 year
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Cairo university
Study officials:
affiliation: Cairo University
name: Cairo University
role: STUDY_CHAIR
References:
Clinical trial NCT01095081: GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients
Official title: GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Magnetic Resonance Imaging
Magnetic Resonance Angiography
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2010-03-29
Enrollment: 23775
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Evaluate the safety and tolerability of Gadovist in patients requiring contrast-enhanced MRI.

Brief summary: Prospective, non-interventional, multi-center study. The observation period for each subject covers the treatment period with Gadovist®. For each patient, the treating physician or nurse documents demographics, medical data, safety parameters and treatment signs and symptoms at the visit. Patients with severe renal impairment will be followed-up after 3 month by phone call from the investigator if in line with routine practice. Data audit/monitoring by source data verification will be done in a subset of sites and patients

Detailed description: Evaluate the safety and tolerability of Gadovist in patients requiring contrast-enhanced MRI.

Eligibility criteria: Inclusion Criteria:

* Patients undergoing contrast enhanced Magnetic Resonance Imaging with Gadobutrol (Gadovist).

Exclusion Criteria:

* There are no other exclusion criteria beyond the contraindications contained in the Summary of Product Characteristics (hypersensitivity to the active substance or to any of the excipients) and the warnings.

Primary outcomes:
measure: Number of Adverse Event Collection / Calculation of Adverse Event rates in Study population and subgroups
timeFrame: 1 day
Secondary outcomes:
measure: Analysis of Adverse Event Collection rates according to age, gender, concomitant diseases and risk factors, dose administered.
timeFrame: 1 day
Other outcomes:
Locations:
city: Many Locations
country: Bosnia and Herzegovina
city: Many Locations
country: Canada
city: Many Locations
country: China
city: Many Locations
country: Czech Republic
city: Many Locations
country: France
city: Many Locations
country: Germany
city: Many Locations
country: Greece
city: Many Locations
country: Hong Kong
city: Many Locations
country: Hungary
city: Many Locations
country: Italy
city: Many Locations
country: Kazakhstan
city: Many Locations
country: Korea, Republic of
city: Many Locations
country: Kyrgyzstan
city: Many Locations
country: Poland
city: Many Locations
country: Russian Federation
city: Many Locations
country: South Africa
city: Many Locations
country: Spain
city: Many Locations
country: Taiwan
city: Many Locations
country: Thailand
city: Many Locations
country: Vietnam
Study officials:
affiliation: Bayer
name: Bayer Study Director
role: STUDY_DIRECTOR
References: